[Treatment of parkinson's syndrome. New developments].
The treatment of Parkinson's syndrome with newly developed drugs has to be planned within the entire therapeutic concept. Besides the anticholinergics, levodopa, amantadines and beta-blockers should be taken into consideration. When necessary, hypnotics, ataractics and antidepressant drugs should be applied.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000547:Amantadine / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D007980:Levodopa / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D010276:Parasympatholytics; D014149:Tranquilizing Agents; D001569:Benzodiazepines; D007980:Levodopa; D000547:Amantadine; D002262:Carboxy-Lyases
Behandlung des Parkinson-Syndroms. Neuentwicklungen.